Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2190)

PROPOSED DISTRIBUTION OF 2025 FINAL DIVIDEND; AND CLOSURE OF H SHARE REGISTER OF MEMBERS

The board (the "**Board**") of directors (the "**Directors**") of Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**") recommends the distribution of the final dividend for the year ended 31 December 2025 of RMB0.22 per share of the Company (the "**Shares**") (tax inclusive) (the "**Proposed 2025 Final Dividend**") in cash to the shareholders of the Company (the "**Shareholders**"). For illustration purpose, assuming no change in the number of issued Shares (excluding treasury shares) during the period from the announcement date to the date of 2025 annual general meeting of the Company ("**2025 AGM**"), the total amount to be paid to the Shareholders for the Proposed 2025 Final Dividend is expected to be approximately RMB74,202,891.40 (tax inclusive), representing approximately 30% of the profit attributable to equity shareholders of the Company for the year ended 2025.

The Proposed 2025 Final Dividend will be submitted to the 2025 AGM for approval. The Proposed 2025 Final Dividend to be distributed will be denominated and announced in Renminbi, of which dividends on domestic Shares and H Shares under the H-Share "Full Circulation" will be paid in Renminbi whereas dividends on other H Shares will be paid in Hong Kong dollars (the exchange rate of Renminbi to Hong Kong dollars will be the average exchange rate as announced by the People's Bank of China for five working days prior to the date of the 2025 AGM).

If the proposal is approved by the Shareholders at the 2025 AGM, the Proposed 2025 Final Dividend is expected to be distributed on or before Thursday, 18 June 2026 to the Shareholders whose names appear on the register of members of the Company on Tuesday, 2 June 2026. The H Shares repurchased by the Company as treasury shares will not be entitled to receive the final dividend.

In order to ascertain the entitlements of the Shareholders to receive the Proposed 2025 Final Dividend, the register of members of the Company will be closed from Friday, 29 May 2026 to Tuesday, 2 June 2026 (both days inclusive), during which period no transfer of H Shares will be registered. The record date will be Tuesday, 2 June 2026. To be eligible to receive the Proposed 2025 Final Dividend, all transfer forms accompanied by the relevant H Share certificates must be lodged with the Company's H share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by no later than 4:30 p.m. on Thursday, 28 May 2026.

A circular containing the information regarding the Proposed 2025 Final Dividend and other resolutions proposed to be considered at the 2025 AGM will be published on the websites of The Stock Exchange of Hong Kong Limited and the Company in due course.

By Order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, March 17, 2026

As at the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.